Laboratory user guide for U.S. public health laboratories : molecular detection of drug resistance (MDDR) in Mycobacterium tuberculosis complex by DNA sequencing (CDC-002-00716)
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


Laboratory user guide for U.S. public health laboratories : molecular detection of drug resistance (MDDR) in Mycobacterium tuberculosis complex by DNA sequencing (CDC-002-00716)

Filetype[PDF-316.06 KB]


  • English

  • Details:

    • Description:
      The ability to detect drug resistance rapidly and accurately in Mycobacterium tuberculosis Complex (MTBC) is critical for the effective treatment of patients suffering from tuberculosis (TB) and relevant interventions of TB control programs. Efforts to treat patients and control the spread of TB can be hindered by the emergence of MTBC resistant to both first- and second-line anti-TB drugs. Additionally, the slow growth rate of MTBC and inherent difficulties associated with conventional drug susceptibility testing methods often serve as impediments to obtaining timely results. Since September 2009, the Laboratory Branch of the Division of Tuberculosis Elimination at U.S. CDC has offered a molecular testing service using conventional DNA sequencing for the identification of drug resistance associated mutations in isolates of MTBC. In June 2012, the service was expanded by incorporating pyrosequencing (PSQ) into the testing algorithm and by accepting nucleic acid amplification test positive (NAAT+) sediments for testing to provide the ability for local providers and programs to potentially further reduce delayed diagnosis of MDR TB. The service allows rapid identification of multidrug-resistant (MDR) TB through the detection of genetic mutations associated with rifampin (RMP) and isoniazid (INH) resistance. In addition, when resistance to RMP is already known or detected in the MDDR service, genetic loci associated with resistance to ethambutol (EMB), pyrazinamide (PZA), and the most effective second-line drugs, fluoroquinolones (FQ) and the injectables amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), are examined. At head of title: "Reference Laboratory, Division of TB Elimination." CDC-002-00716v01 Effective: 1/3/2022 mddrusersguide.pdf
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov